Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Growth Metrics
Income Statement
Others
Ratios

Northwest Biotherapeutics (NWBO) Change in Cash (2016 - 2025)

Northwest Biotherapeutics (NWBO) has 16 years of Change in Cash data on record, last reported at $244000.0 in Q3 2025.

  • For Q3 2025, Change in Cash rose 320.69% year-over-year to $244000.0; the TTM value through Sep 2025 reached $1.6 million, up 151.33%, while the annual FY2024 figure was $49000.0, 101.01% up from the prior year.
  • Change in Cash reached $244000.0 in Q3 2025 per NWBO's latest filing, down from $1.5 million in the prior quarter.
  • Across five years, Change in Cash topped out at $11.3 million in Q4 2021 and bottomed at -$8.2 million in Q1 2022.
  • Average Change in Cash over 5 years is -$285421.1, with a median of $58000.0 recorded in 2024.
  • Peak YoY movement for Change in Cash: crashed 741.58% in 2021, then skyrocketed 5789.74% in 2022.
  • A 5-year view of Change in Cash shows it stood at $11.3 million in 2021, then plummeted by 121.71% to -$2.5 million in 2022, then plummeted by 61.42% to -$4.0 million in 2023, then skyrocketed by 80.76% to -$764000.0 in 2024, then surged by 131.94% to $244000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Change in Cash were $244000.0 in Q3 2025, $1.5 million in Q2 2025, and $604000.0 in Q1 2025.